Fulgent Genetics Reports First Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500 volatile in choppy trading; Mideast deal, SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Fulgent Genetics, Inc. (FLGT) Tops Q1 EPS by $1.66, Lowers FY22 EPS Guidance
May 3, 2022 4:26 PM EDTFulgent Genetics, Inc. (NASDAQ: FLGT) reported Q1 EPS of $5.08, $1.66 better than the analyst estimate of $3.42. Revenue for the quarter came in at $320.3 million versus the consensus estimate of $244.65 million.
GUIDANCE:
Fulgent Genetics, Inc. sees FY2022 EPS of $6.00, versus the consensus of... More
